Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast - 2028
|発行||DelveInsight Business Research LLP||商品コード||911508|
|出版日||ページ情報||英文 125 Pages
|酸性スフィンゴミエリナーゼ欠損症（ASMD）：市場洞察、疫学、市場予測 2028年 Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast - 2028|
|出版日: 2019年09月01日||ページ情報: 英文 125 Pages||
DelveInsight's 'Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ASMDs in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acid sphingomyelinase deficiency (ASMD) from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
Acid sphingomyelinase deficiency (ASMD) is a rare progressive genetic disorder that results from a deficiency of the enzyme acid sphingomyelinase, which is required to break down (metabolize) a fatty substance (lipid) called sphingomyelin and inherited in an autosomal recessive pattern. Acid sphingomyelinase, E.C. 126.96.36.199, (ASM) is a lysosomal phosphodiesterase enzyme that hydrolyzes sphingomyelin, a phospholipid storage substance found in the brain, liver, lungs, spleen and lymph nodes, to ceramide and phosphorylcholine. It is also known as Niemann-Pick disease.
The DelveInsight Acid sphingomyelinase deficiency (ASMD) market report gives the thorough understanding of the Acid sphingomyelinase deficiency by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acid sphingomyelinase deficiency in Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.
The Acid sphingomyelinase deficiency (ASMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations) scenario of Acid sphingomyelinase deficiency (ASMD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.
According to DelveInsight, the total number of prevalent cases of Acid sphingomyelinase deficiency (ASMD) in 10 EM was found to be 8,799, in the year 2017.
This segment of the Acid sphingomyelinase deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The treatment scenario in emerging markets is more or less same as in the United States and Europe. There is a tremendous lack of effective supportive therapies (especially for the infantile cases), let alone curative ones with the severe infantile neurovisceral phenotype encountering death by 3 years of age. Although the other less severe forms have a normal lifespan but a certain section die prematurely due to respiratory insufficiency and liver disease. Statins form the mainstay of treatment regimen used to treat hyperlipidemia characterized by low high-density lipoprotein (HDL) cholesterol in NPD Type B adult cases.
The Acid sphingomyelinase deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Acid sphingomyelinase deficiency in 10EM was found to be USD 1.2 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Acid sphingomyelinase deficiency, in comparison to Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, and Taiwan.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.